Variability in magnitude and direction of discordance between continuous glucose monitoring (CGM) metrics and traditional biomarkers in patients with diabetes and end-stage kidney disease (ESKD): A case series.

In four patients with diabetes and end-stage kidney disease, glycated hemoglobin A1c (HbA1c) showed marked, time-varying discordance with continuous glucose monitoring (CGM)-derived glucose management indicator, ranging from - 2.1% to + 6.2%. Anemia, erythropoiesis-stimulating therapy, iron disturbances, hemoglobinopathy, transfusion and glycemic variability contributed, supporting CGM metrics for safer assessment and treatment adjustment.